Skip to main content

Table 2 Clinicopathological characteristics according to PI3K/RAS-RAF pathway gene mutation status in 214 (212) colorectal cancer patients

From: BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients

   KRAS exon 2 BRAF exon 15 PIK3CA exon 9&20* PI3K/RAS-RAF pathway*
   No. patients (214/212) No (%) Yes (%) P No (%) Yes (%) P No (%) Yes (%) P No (%) Yes (%) P
Sex male 127 (126) 73 (61.9) 54 (56.3) 0.406a 122 (59.5) 5 (55.6) 1.000b 109 (58.6) 17 (65.4) 0.509a 60 (61.2) 66 (57.9) 0.623a
  female 87 (86) 45 (38.1) 42 (43.8)   83 (40.5) 4 (44.4)   77 (41.4) 9 (34.6)   38 (38.8) 48 (42.1)  
Age   68.0 67.1 69.1 0.286d 68.0 66.9 0.801d 68.7 64.6 0.133d 67.8 68.4 0.728d
Location colon 126 (124) 73 (61.9) 53 (55.2) 0.325a 117 (57.1) 9 (100.0) 0.011 b 103 (55.4) 21 (80.8) 0.014 a 54 (55.1) 70 (61.4) 0.353a
  rectum 88 (88) 45 (38.1) 43 (44.8)   88 (42.9) 0 (0)   83 (44.6) 5 (19.2)   44 (44.9) 44 (38.6)  
Differentiation well 29 (29) 19 (16.1) 10 (10.4) 0.912c 28 (13.7) 1 (11.1) 0.131c 22 (11.8) 7 (26.9) 0.215c 15 (15.3) 14 (12.3) 0.521c
  moderate 163 (161) 83 (70.3) 80 (83.3)   159 (77.6) 4 (44.4)   145 (78.0) 16 (61.5)   73 (74.5) 88 (77.2)  
  poor 7 (7) 7 (5.9) 0 (0)   5 (2.4) 2 (22.2)   5 (2.7) 2 (7.7)   3 (3.1) 4 (3.5)  
  missing 15 (15) 9 (7.6) 6 (6.3)   13 (6.3) 2 (22.2)   14 (7.5) 1 (3.8)   7 (7.1) 8 (7.0)  
Tumor diameter <5 cm 103 (102) 53 (44.9) 50 (52.1) 0.254c 101 (49.3) 2 (22.2) 0.171b 93 (50.0) 9 (34.6) 0.172a 46 (46.9) 56 (49.1) 0.710a
  > = 5 cm 108 (107) 64 (54.2) 44 (45.8)   101 (49.3) 7 (77.8)   91 (48.9) 16 (61.5)   51 (52.0) 56 (49.150.0)  
  missing 3 (3) 1 (0.8) 2 (2.1)   3 (1.5) 0 (0)   2 (1.1) 1 (3.8)   1 (1.0) 2 (1.8)  
TNM-stage I 32 (32) 15 (12.7) 17 (17.7) 0.828c 32 (15.6) 0 (0) 0.007 c 26 (14.0) 6 (23.1) 0.433c 13 (13.3) 19 (16.7) 0.231c
  II 78 (77) 50 (42.4) 28 (29.2)   76 (37.1) 2 (22.2)   69 (37.1) 8 (30.8)   44 (44.9) 33 (28.9)  
  III 82 (81) 38 (32.2) 44 (45.8)   79 (38.5) 3 (33.3)   70 (37.6) 11 (42.3)   31 (31.6) 50 (43.9)  
  IV 19 (19) 13 (11.0) 6 (6.3)   15 (7.3) 4 (44,4)   18 (9.7) 1 (3.8)   8 (8.2) 11 (9.6)  
  missing 3 (3) 2 (1.7) 1 (1.0)   3 (1.5) 0 (0)   3 (1.6) 0 (0)   2 (2.0) 1 (0.9)  
T T1 5 (5) 4 (3.4) 1 (1.0) 0.236c 5 (2.4) 0 (0) 0.057c 5 (2.7) 0 (0) 0.808c 4 (4.1) 1 (0.9) 0.724c
  T2 35 (35) 15 (12.7) 20 (20.8)   35 (17.1) 0 (0)   29 (15.6) 6 (23.1)   13 (13.3) 22 (19.3)  
  T3 167 (166) 93 (78.8) 74 (77.1)   159 (77.6) 8 (88.9)   147 (79.0) 19 (73.1)   77 (78.6) 89 (78.1)  
  T4 5 (4) 4 (3.4) 1 (1.0)   4 (2.0) 1 (11.1)   3 (1.6) 1 (3.8)   2 (2.0) 2 (1.8)  
  missing 2 (2) 2 (1.7) 0 (0)   2 (1.0) 0 (0)   2 (1.1) 0 (0)   2 (2.0) 0 (0)  
N N(−) 115 (114) 70 (59.3) 45 (46.9) 0.050 a 113 (55.1) 2 (22.2) 0.083b 99 (53.2) 15 (57.7) 0.710a 61 (62.2) 53 (46.5) 0.013 a
  N(+) 97 (96) 46 (39.0) 51 (53.1)   90 (43.9) 7 (77.8)   85 (45.7) 11 (42.3)   35 (35.7) 61 (53.5)  
  missing 2 (2) 2 (1.7) 0 (0)   2 (1.0) 0 (0)   2 (1.1) 0 (0)   2 (2.0) 0 (0)  
Metastases M(−) 163 (161) 88 (74.6) 75 (78.1) 0.367a 159 (77.6) 4 (44.4) 0.037 b 144 (77.4) 17 (65.4) 1.808a 77 (78.6) 84 (73.7) 0.689a
  M(+) 51 (51) 30 (25.4) 21 (21.9)   46 (22.4) 5 (55.6)   42 (22.6) 9 (34.6)   21 (21.4) 30 (26.3)  
Synchronous metastases M(−) 193 (191) 104 (88.1) 89 (92.7) 0.224a 188 (91.7) 5 (55.6) 0.004 b 166 (89.2) 25 (96.2) 0.479b 89 (90.8) 102 (89.5) 0.708a
  M(+) 19 (19) 13 (11.0) 6 (6.3)   15 (7.3) 4 (44.4)   18 (9.7) 1 (3.8)   8 (8.2) 11 (9.6)  
  missing 2 (2) 1 (0.8) 1 (1.0)   2 (1.0) 0 (0)   2 (1.1) 0 (0)   1 (1.0) 1 (1.0)  
Metachronous metastases M(−) 176 (174) 95 (80.5) 81 (84.4) 0.462a 171 (83.4) 5 (55.6) 0.055b 156 (83.9) 18 (69.2) 0.097b 82 (83.7) 92 (80.7) 0.574a
  M(+) 38 (38) 23 (19.5) 15 (15.6)   34 (16.6) 4 (44.4)   30 (16.1) 8 (30.8)   16 (16.3) 22 (19.3)  
  1. achi-square test; bFisher exact test; cMann–Whitney test; dt test; *DNA of two samples were not available for PIK3CA exon 20. P-values ≤ 0.05 are in bold.